EGFR and non-small cell lung carcinoma: Reducing the expression of EGFR can effectively inhibit the resistance of NSCLC to EGFR tyrosine kinase inhibitors (EGFR-TKIs) by suppressing p-EGFR and the EGFR signaling pathway [17,18].